^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    WNT974

    i
    Company:
    Novartis
    Drug class:
    Wnt signalling pathway inhibitor, PORCN inhibitor
    Related drugs:
    Apply
    A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (NCT01351103)
    Phase 1
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    05/30/2024
    Initiation :
    12/01/2011
    Primary completion :
    06/14/2021
    Completion :
    06/18/2024
    BRAF • RNF43
    |
    BRAF mutation • RNF43 mutation
    |
    spartalizumab (PDR001) • WNT974
    Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations (NCT02278133)
    Phase 1/2
    Array BioPharma
    Completed
    Last update posted :
    10/09/2017
    Initiation :
    12/01/2014
    Primary completion :
    05/31/2016
    Completion :
    06/23/2017
    KRAS • RNF43
    |
    KRAS mutation • BRAF V600 • KRAS wild-type • RAS wild-type • RNF43 mutation
    |
    Erbitux (cetuximab) • Braftovi (encorafenib) • WNT974